Asma Khalid, MD Family Medicine - Geriatric Medicine Medicare: Medicare Enrolled Practice Location: 621 S 4th St, Le Sueur, MN 56058 Phone: 507-665-3375 |
Erin Cheyenne Westfall, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 625 S 4th St, Le Sueur, MN 56058 Phone: 507-665-6299 |
Carolyn D Stelter, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 625 S 4th St, Le Sueur, MN 56058 Phone: 507-665-6299 |
Timothy J Halloran, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 N Main St, Suite 101, Le Sueur, MN 56058 Phone: 507-665-4017 Fax: 507-665-4019 |
News Archive
Promethera Biosciences SA, a world-leading cell therapy and regenerative medicine company targeting liver diseases, today announced the presentation of new preclinical NASH-Fibrosis data from its proprietary HepaStem program, demonstrating a beneficial effect of HepaStem in a nonalcoholic steatohepatitis (NASH) mouse model and confirming Hepastem's unique and multifaceted mode of action.
If the word's nations are going to prevent tobacco smoking from causing one projected billion deaths by the end of this century, they must: Make tobacco control part of the agendas of United Nation's and other development agencies worldwide; Assure every sector of a nation including health, trade and finance officials work collectively to protect not only health but the harm tobacco places on their economy by passing laws to reduce use; Place health as the centerpiece of any decision on a trade treaty that includes tobacco; Diligently work toward a goal of reducing the prevalence rate of smoking to less than five percent world-wide by 2048, basically ending its use.
The John Theurer Cancer Center at Hackensack University Medical Center unveiled a new $130-million, 155,000-square-foot comprehensive cancer facility that will enhance the cancer center's ability to deliver multidisciplinary extraordinary care, best-in-class clinical quality, and cutting-edge research. The doors will open for patients in January 2011.
Our tissues are able to form new blood vessels throughout life. This mechanism, which is called angiogenesis, is essential notably in the case of myocardial infarction, stroke and limb ischemia. The very same mechanism, however, keeps tumors supplied with nutrients and oxygen thus enabling them to continue growing.
Biogen Idec and Portola Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop and commercialize highly selective, novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
› Verified 4 days ago